Open-label, Multicenter Trial of RSV Vaccination to Reduce Moderate-to-severe Exacerbations in COPD Frequent Exacerbators: Clinical Effectiveness and RSV-specific Immune Responses

Objectives: To determine whether respiratory syncytial virus (RSV) vaccination reduces the rate of all-cause moderate-to-severe acute exacerbations of COPD (AECOPD) in high-risk patients, and to characterise RSV-specific infection and immune responses in this population.
Hypothesis: RSV vaccination in COPD frequent exacerbators receiving dual long-acting bronchodilators will reduce all-cause moderate-to-severe AECOPD by at least 20-25% over 12 months.
Design and subjects: This multicentre, two-arm, open-label, prospective study will recruit 320 COPD patients with 2 moderate or severe AECOPD in the prior year despite dual long-acting bronchodilator therapy. Eligible subjects will be allocated 1:1 to receive RSV vaccination plus standard care or standard care alone and followed for 12 months.
Interventions: Participants in the vaccine arm will receive a single dose of a licensed RSV vaccine in addition to usual COPD management. Controls will receive usual care without RSV vaccination during the study period.
Main outcome measures: The primary outcome is the rate of all-cause moderate-to-severe AECOPD per patient-year. Secondary outcomes include RSV-positive AECOPD, RSV infection incidence confirmed by virological testing, severe AECOPD requiring hospitalisation, time to first moderate-to-severe AECOPD, and changes in plasma RSV-specific antibody titres over 12 months.
Data analysis and expected results: Exacerbation rates will be compared between groups using negative binomial regression with adjustment for key covariates on an intention-to-treat basis. The investigators expect RSV vaccination to achieve a clinically meaningful (20%) reduction in all-cause moderate-to-severe AECOPD and to provide mechanistic insights linking RSV immunity, RSV infection, and exacerbation risk in COPD frequent exacerbators.

Start Date01 Jul 2027

Sponsor / Collaborator

The Chinese University of Hong Kong

[+1]

NCT07712380

/ Not yet recruitingPhase 2

A Randomized, Observer-blind, Placebo-controlled Exploratory Study to Evaluate Whether Administration of Adjuvanted RZV or RSVPreF3 Vaccine Can Attenuate Coronary Plaque Progression in Individuals 50 Years of Age and Above Who Are at Risk for Cardiovascular Events

This study is designed to evaluate whether the adjuvanted recombinant zoster vaccine (RZV) or the adjuvanted respiratory syncytial virus PreFusion protein 3 (RSVPreF3) vaccine can attenuate the progression of coronary plaque in adult individuals at risk for cardiovascular events.

Start Date23 Oct 2026

Sponsor / Collaborator

GSK Plc

NCT07863401

/ Not yet recruitingPhase 2IIT

Immunogenicity and Safety of Two Respiratory Syncytial Virus Vaccine Strategies in Lung and Allogeneic Haematopoietic Stem Cell Transplant Recipients: A Phase 2 Trial

Respiratory syncytial virus (RSV) is a major cause of acute respiratory infections (ARIs), which occur in seasonal outbreaks. Among the adult population, immunocompromised individuals, particularly lung transplant recipients and recipients of allogeneic haematopoietic stem cell transplants (HSCTs), are at the highest risk of severe ARI. RSV can also cause prolonged inflammation of the airways, leading to persistent deterioration in lung function. Thus, in lung transplant recipients, RSV is a major cause of chronic lung allograft dysfunction (CLAD), the leading cause of lung transplant failure and mortality beyond the first post-transplant year. In recipients of ACSH, RSV infection is associated with the onset and/or worsening of bronchiolitis obliterans syndrome, which leads to increased mortality. Preventing RSV-associated lower respiratory tract disease (LRTD) and its short- and long-term consequences in these populations is therefore a key priority.
Three inactivated RSV vaccines, targeting the RSV fusion glycoprotein in its pre-fusion conformation (RSVpreF), have recently been approved for use in adults. These comprise two recombinant protein vaccines - one with an adjuvant (RSVpreF3-AS01, Arexvy®, GSK) and one without (RSVpreF, Abrysvo®, Pfizer) - and one mRNA vaccine. Although these vaccines have demonstrated their safety, immunogenicity and efficacy (reducing the risk of RSV-related IMRI by approximately 80-85 per cent) in adults aged 60 and over, the pivotal trials excluded immunocompromised patients.
To date, there is limited data on the efficacy, immunogenicity and tolerability of these vaccines in high-risk immunocompromised populations, such as recipients of bone marrow transplants and allogeneic stem cell transplants. Real-world studies suggest that RSV vaccines may reduce the risk of RSV-associated acute respiratory infection and hospitalisations in elderly immunocompromised adults. With regard to immunogenicity, the available cohort studies, conducted on small sample sizes, indicate that the vaccine response is heterogeneous and, overall, lower than that observed in immunocompetent older people. Preliminary data suggest that booster vaccination regimens may be necessary to optimise the immune response in these populations.
Given the significant morbidity associated with RSV in recipients of bone marrow transplants and allogeneic stem cell transplants, it is a priority to assess the immunogenicity and safety profile of RSV vaccines, and to determine the optimal vaccination schedule for these high-risk, immunocompromised populations.
The investigators hypothesise that the immune response to RSV vaccines in severely immunocompromised TP and ACSH recipients is weaker than in immunocompetent older adults, and that enhanced vaccination strategies may be required. In this study, two vaccination strategies will be evaluated in these populations:
* a single dose of the adjuvanted RSVpreF3-AS01 vaccine (Arexvy®),
* or a booster regimen comprising two doses of the non-adjuvanted RSVpreF vaccine (Abrysvo®), administered one month apart.

Start Date01 Oct 2026

Sponsor / Collaborator

Hospices Civils de Lyon

100 Clinical Results associated with Respiratory Syncytial Virus Vaccine (GSK)

100 Translational Medicine associated with Respiratory Syncytial Virus Vaccine (GSK)

100 Patents (Medical) associated with Respiratory Syncytial Virus Vaccine (GSK)

Literatures (Medical) associated with Respiratory Syncytial Virus Vaccine (GSK)

31 Dec 2026·Human Vaccines & Immunotherapeutics

Quantifying vaccine dissemination for uptake comparisons between vaccines

Article

Author: Dirks, Abigail ; Getz, Ken ; Ford, Madison ; Do, Hana

Vaccine hesitancy is a complex public health concern, but it has been difficult to characterize and monitor the speed of uptake of individual vaccines. The study was aimed to determine whether vaccine uptake can be quantified and mapped to individual vaccines and to consider methods for comparing vaccine uptake between vaccines. Vaccines assessed were selected based on their similarity to COVID-19 and the 2020 pandemic by the following criteria: the vaccine impacts the broader public and has global health effects, was approved between 2006 and 2024, protects against a virus, and does not follow a seasonal pattern, unless it had a significant outbreak between 2006 and 2024 before it became a seasonal vaccine. Main outcomes included diffusion curves of each vaccine, both in terms of estimated global units dispensed and estimated proportion of the US population that is vaccinated. Metrics included average units dispensed globally per month, mean coverage of the target population, maximum coverage of the target population, and rate of change in number of vaccinations over time. Metrics are estimates which rely on sales data and imputation. Diffusion curves were mapped for individual vaccines, and five vaccines were determined to have the fastest relative uptake, although not all differences were statistically significant. The five vaccines were Arexvy, Comirnaty, Gardasil/Gardasil 9, Heplisav-B, and the ID Biomedical H1N1 Monovalent Vaccine. Collection, mapping, and analysis of estimated vaccine diffusion curves inform understanding of vaccine hesitancy and the impact of strategies and tactics to improve and accelerate vaccine uptake.

07 Oct 2026·CLINICAL INFECTIOUS DISEASES

Immunogenicity and Safety of the Adjuvanted Respiratory Syncytial Virus Prefusion F Protein-Based Vaccine When Co-administered With the Adjuvanted Recombinant Herpes Zoster Subunit Vaccine in Adults ≥ 50 Years of Age

Article

Author: Surber, Joseph G ; Jastorff, Archana M ; Lee, Theodore ; David, Marie-Pierre ; Smith, Brian A ; Roussy, Jean-François ; Aggarwal, Naresh ; Gupta, Anil K ; Gérard, Catherine ; Abitbol, Alexander ; Wallace, Garry ; Hailemariam, Hiwot Amare ; Van der Wielen, Marie ; Dennis, Patrick

Abstract:

Background:

Co-administration of AS01E-adjuvanted respiratory syncytial virus vaccine (adjuvanted RSVPreF3) and AS01B-adjuvanted recombinant herpes zoster subunit vaccine (RZV), although not contraindicated, has not been previously studied in clinical trials.

Methods:

This phase III, open-label, randomized (1:1) trial evaluated the immunogenicity, safety, and reactogenicity of adjuvanted RSVPreF3 when co-administered with RZV in ≥50-year-olds. The 2 vaccines were either co-administered at visit 1 (day [D] 1; Co-Ad), or were given sequentially, 1 month apart (RZV dose 1 at D1, adjuvanted RSVPreF3 at D31; Control). All participants received RZV dose-2 at D61. Non-inferiority of humoral immune responses was demonstrated if 95% confidence interval (CI) upper limits for geometric mean RSV-A/B neutralizing titers (GMT) and varicella-zoster virus anti-glycoprotein E (anti-gE) antibody concentration (GMC) ratios (Control/Co-Ad) were ≤1.5. Safety and reactogenicity were secondary endpoints.

Results:

Overall, 530 participants (Co-Ad = 265; Control = 265) were vaccinated. Neutralizing GMT ratios for RSV-A (1.1 [95% CI = 1.0–1.4]) and RSV-B (1.0 [0.8–1.2]), and anti-gE antibody GMC ratio (1.2 [1.1–1.4]) met non-inferiority criteria. Within 7 days post-vaccination, 71.7% (Co-Ad: post-RZV dose 1 and adjuvanted RSVPreF3; grade [Gr] 3 = 3.9%), 58.5% (Control: post-RZV dose 1; Gr3 = 1.9%), and 47.8% (Control: post-adjuvanted RSVPreF3; Gr3 = 1.2%) of participants reported solicited administration-site adverse events (AEs). Post-visit 1, 73.6% (Gr3 = 9.3%) of Co-Ad and 60.4% (Gr3 = 6.2%) of control participants reported solicited systemic AEs. Within 30 days post-any vaccination, 23.4% (Gr3 = 0.8%) of Co-Ad and 30.2% (Gr3 = 1.1%) of control participants reported unsolicited AEs. No fatal or related serious AEs were reported.

Conclusions:

Immunogenicity, reactogenicity, and safety data support the co-administration of adjuvanted RSVPreF3 and RZV.

Clinical Trials Registration:

NCT05966090.

01 Sep 2026·ERJ Open Research

Adjuvanted RSVPreF3 vaccine impact over three respiratory syncytial virus seasons in older adults with comorbidities

Article

Author: Feldman, Robert G ; David, Marie-Pierre ; Halpin, David M G ; Papi, Alberto ; Lee, Dong-Gun ; Ison, Michael G ; Antonelli Incalzi, Raffaele ; Schwarz, Tino F ; Fissette, Laurence ; Kotb, Shady ; Michaud, Jean-Philippe ; Olivier, Aurélie ; Maréchal, Céline ; Hulstrøm, Veronica ; Xavier, Stebin ; Van der Wielen, Marie

Background:

We explored the efficacy of AS01 E -adjuvanted respiratory syncytial virus prefusion F protein-based vaccine (adjuvanted RSVPreF3) in subpopulations of participants with underlying medical conditions in the multi-country, phase 3 AReSVi-006 trial (conducted between May 2021 and May 2024).

Methods:

Medically stable ≥60-year-olds were 1:1-randomised to receive one adjuvanted RSVPreF3 or placebo dose pre-RSV season 1. In exploratory post hoc analyses in subgroups of participants with underlying conditions (including COPD, asthma, diabetes and obesity (body mass index ≥30 kg·m −2 )), we evaluated efficacy of one vaccine dose against RSV-related lower respiratory tract disease (RSV-LRTD), RSV-related acute respiratory illness (RSV-ARI) and RSV-ARI-related complications ( e.g. , pneumonia, COPD/asthma exacerbation and cardiovascular events). We also evaluated ( post hoc ) RSV-ARI-related systemic corticosteroid and antibiotics use in participants with COPD or asthma.

Results:

The efficacy analyses comprised 12 468 vaccine and 12 498 placebo recipients. Efficacy against RSV-LRTD over three RSV seasons was similar among participants with COPD (75.1%, 95% CI: 40.2–91.4), asthma (65.8%, 31.0–84.7), diabetes (69.8%, 37.5–87.1) and obesity (74.1%, 56.4–85.5) as in the overall study population (62.9%, 97.5% CI: 46.7–74.8). Efficacy was also observed against RSV-ARI in these subgroups. Efficacy against RSV-ARI-related complications was 74.4% (95% CI: 11.2–95.2) in participants with COPD and 60.8% (−9.9–88.7) in those with asthma. Among participants with COPD, 15.4% (1.9–45.4) of RSV-ARI episodes in vaccine versus 22.4% (12.5–35.3) in placebo recipients were treated with systemic corticosteroids, and 46.2% (19.2–74.9) versus 56.9% (43.2–69.8) with antibiotics.

Conclusions:

Post hoc analyses of the AReSVi-006 trial suggest that adjuvanted RSVPreF3 may help prevent RSV-ARI, RSV-LRTD and RSV-related complications in medically stable older adults with underlying medical conditions like COPD and asthma.

314

News (Medical) associated with Respiratory Syncytial Virus Vaccine (GSK)

07 Sep 2026

·firstwordpharma.com

Clover posts upbeat mid-stage data for respiratory vaccine combos

Clover Biopharmaceuticals over the weekend announced favourable preliminary results from a mid-stage study of its combination vaccine candidates for respiratory infections, moving them closer to pivotal trials. "The…results significantly de-risk future late-stage development," said CEO Joshua Liang, while also validating "our differentiated Trimer-Tag platform for the development of multi-valent protein-based respiratory vaccines."The Phase II trial investigated SCB-1022, which is designed to provide protection against respiratory syncytial virus (RSV) and human metapneumovirus (hMPV), and SCB-1033, which, along with RSV and hMPV, is also designed to immunise recipients against human parainfluenza virus type 3 (PIV3).The study randomised 420 adults across Australia aged 60-85 years to receive SCB-1022, SCB-1033 or placebo. Results showed that at 28 days following vaccination, the geometric mean fold increases in neutralising antibodies from the pre-vaccination baseline were approximately 6-9 fold for RSV, 6-8 fold for hMPV, and more than three-fold for PIV3 — rising to roughly five-fold among participants with low baseline PIV3 antibody levels. Notably, Clover said there was no drop-off in antibody responses among participants aged 75 and over compared with those aged 60-74, and no immune interference on RSV and hMPV responses was seen with the addition of the PIV3 antigen to SCB-1033.Furthermore, the vaccine groups demonstrated an approximately 62% lower rate of respiratory tract infections versus placebo within 28 days — at a time when an RSV outbreak with co-circulating hMPV and PIV was active in Australia.Safety-wise, both vaccines were generally well tolerated, with the most common adverse events being fatigue, headache and injection site pain, which lasted around two days. No vaccine-related serious adverse events or discontinuations were reported.The Shanghai-based biotech noted it would continue assessing mid- and late-stage development plans for the two candidates, while also exploring potential global collaboration opportunities. Previously, the company's standalone RSV vaccine asset, SCB-1019, showed encouraging early-stage results in a head-to-head comparison with GSK's adjuvanted vaccine Arexvy.

Clinical ResultPhase 2Vaccine

25 Aug 2026

·allsci.com

CSPC's RSV vaccine clears FDA for US trials weeks after China approval

SYS6057, a recombinant respiratory syncytial virus (RSV) vaccine candidate developed by CSPC Pharmaceutical Group (HKEX: 01093), has received FDA clearance to begin clinical trials in the US, less than a month after China's National Medical Products Administration (NMPA) granted the same authorization on 30 July 2026. The back-to-back regulatory clearances give the Hong Kong-listed company a simultaneous development path in two of the world's largest markets for RSV prophylaxis in older adults. SYS6057 combines the RSV prefusion F (Pre-F) protein antigen with a proprietary second-generation nano-adjuvant system. CSPC says the adjuvant uses a different nanocarrier compared with its earlier RSV vaccine candidate, conferring distinct physicochemical and immunological properties. Preclinical data, according to the company, showed the vaccine can simultaneously elicit high-titre neutralising antibodies and cellular immune responses — a dual-arm immune profile the company attributes to adjuvant optimization. No clinical efficacy or safety data have been disclosed. The planned clinical development in both countries targets prevention of RSV-associated lower respiratory tract disease in adults aged 60 and older. Trial design, participant numbers, dosing, and primary endpoints have not been disclosed. CSPC enters a market where three RSV vaccines are already approved in the US for older adults: GSK's Arexvy (RSVPreF3-AS01E), Pfizer's Abrysvo (RSVpreF), and Moderna's mRESVIA (mRNA-1345), first approved in May 2023, May 2023, and May 2024, respectively. Arexvy and Abrysvo use prefusion F protein antigens, while mRESVIA uses mRNA encoding the prefusion F protein. SYS6057 similarly targets prefusion F but combines the recombinant antigen with CSPC's proprietary nano-adjuvant system, broadly resembling Arexvy's protein-plus-adjuvant strategy while using different adjuvant technology. CSPC describes SYS6057 as its second recombinant protein vaccine candidate to enter clinical trials. Spot something wrong? Report an issue with this article

VaccineDrug ApprovalmRNAINDClinical Study

03 Aug 2026

·www.pharmaindustrial-india.com

GSK India Reports 24 Percent PAT Growth in Q1 FY27

GlaxoSmithKline (GSK) Pharmaceuticals has announced its financial results for the first quarter ended June 30, 2026. During the quarter, the company delivered strong growth across both its core and innovative portfolios. The performance reflects continued progress in the company's portfolio transformation strategy, supplemented by execution excellence, and a favorable base effect from the comparable period last year. Revenue for the quarter stood at INR 924 crore, up 15 percent Year-on-Year (YoY). Profit After Tax (PAT) increased by 24 percent to INR 253 crore, while EBITDA margins stood at 32 percent. The General Medicines portfolio grew strongly during the quarter, with the top 5 promoted brands outperforming the market (EI* >100; Source: IQVIA). Key promoted brands such as Augmentin, Ceftum and T-Bact reinforced their leadership positions in their respective categories, driven by a combination of deeper scientific and in-clinic engagement, omnichannel execution, and pricing measures. The Respiratory portfolio continued to further the management of chronic respiratory diseases with Nucala (mepolizumab) benefitting a large number of patients and Trelegy Ellipta gaining traction through new access pathways. The vaccines business grew through continued leadership in the self-pay private pediatric vaccines market, led by Infanrix Hexa and Fluarix Tetra. In the adult vaccination space, the company’s focus on elderly patient-cohorts with underlying Cardiovascular and Metabolic Diseases (CVMD) led to stronger endorsement from the healthcare professional community, translating to higher vaccinations with Shingrix (Recombinant Herpes Zoster Vaccine, Adjuvanted). The oncology business, led by specialised therapies Jemperli (dostarlimab) and Zejula (niraparib), has grown significantly since its launch in August last year. Jemperli is now the leading immunotherapy for first line primary advanced and recurrent endometrial cancer while Zejula is among the top PARP inhibitors in the maintenance treatment of recurrent ovarian cancer. Together, both therapies have touched the lives of a growing number of women suffering from gynecological malignancies, with GSK committed to expanding access and patient reach. Commenting on the results, Bhushan Akshikar, Managing Director (MD), GSK India, said, "GSK India's broad-based growth demonstrates the resilience of the core General Medicines and Vaccines portfolio and the growing contribution of the innovative business. This growth was enabled by a relentless focus on scientific excellence, sharper execution in the field and meaningful investments in technology and talent development. With a strong innovation pipeline and launch opportunities ahead, we are well-positioned to deliver sustainable growth and meaningful impact for millions of patients in India." The company has made progress in strengthening supply chain resilience through diversified sourcing, enhanced contingency planning and improved end-to-end visibility, substantially mitigating disruptions experienced in recent quarters. Looking ahead, GSK India is preparing for key pipeline launches. Blenrep (belantamab mafodotin), an anti-BCMA ADC therapy indicated for second-line treatment in relapsed or refractory multiple myeloma in adults, is set for launch. Arexvy, a vaccine to prevent Lower Respiratory Tract Disease (LRTD) caused by Respiratory Syncytial Virus (RSV) in adults over 60 years of age and older adults (50 to 59 years) at high-risk, has received Marketing Authorisation (MA).

VaccineDrug ApprovalFinancial Statement

100 Deals associated with Respiratory Syncytial Virus Vaccine (GSK)

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Respiratory Diseases	United States	GlaxoSmithKline Biologicals SA	10 Jun 2024
Lower Respiratory Tract Infections	United States	GlaxoSmithKline Biologicals SA	03 May 2023
Respiratory Syncytial Virus Infections	United States	GlaxoSmithKline Biologicals SA	03 May 2023

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT06614725 (CTgov)	Phase 3	Respiratory Syncytial Virus Infections	751	RSVPreF3 OA investigational vaccine (OA-RSV Group)	jxrnfvokzb(qjilnvbdyt) = yqxpdbrrzj pwkqtnsknb (tynuuidjyz, faytwwuyju - ppgokfvfhx) View more	-	23 Jun 2026
				Placebo (OA-Placebo Group)	jxrnfvokzb(qjilnvbdyt) = kjhzrxeple pwkqtnsknb (tynuuidjyz, nqgmitoniy - etpljjmkgy) View more
NCT06551181 (CTgov)	Phase 3	Respiratory Syncytial Virus Infections	2,620	RSVPreF3 OA investigational vaccine (RSV OA Vaccine Group (China))	nqopscxoxi(cxtxpulade) = oytslaqodm dhmtcenogo (jvdjawcieq, ugnjcmqqrp - mygmgygfkq) View more	-	19 May 2026
				RSVPreF3 OA investigational vaccine (RSV OA Vaccine Group (Overseas))	nqopscxoxi(cxtxpulade) = eaisitnvpr dhmtcenogo (jvdjawcieq, okqvfkeobd - aukqwghmhq) View more
NCT06374394 (CTgov)	Phase 3	Respiratory Syncytial Virus Infections	841	COVID-19 mRNA vaccine+RSVPreF3 OA investigational vaccine (Co-Ad Group)	fihnzcguzi(nfdjpoffrg) = qnidswrsfy jcjtdtkwce (pycgwqerii, obdkiqbldh - lafxrnqzxc) View more	-	26 Dec 2025
				COVID-19 mRNA vaccine+RSVPreF3 OA investigational vaccine (Control Group)	fihnzcguzi(nfdjpoffrg) = dzssiieele jcjtdtkwce (pycgwqerii, jouqhngxaf - fmlqhjljgd) View more
NCT06389487 (CTgov)	Phase 3	Respiratory Syncytial Virus Infections	1,459	RSVPreF3 OA investigational vaccine (Part A: RSV-A-AIR Group)	sdvnlusxqf(odciyoxtpq) = jntcwncwio fyomkkcqqg (xxcathanvq, wnwmqrvtjr - dnlushffvv) View more	-	25 Sep 2025
				RSVPreF3 OA investigational vaccine (Part A: RSV-OA Group)	sdvnlusxqf(odciyoxtpq) = dlljgxbaxc fyomkkcqqg (xxcathanvq, harpueuxlc - agptjodmqz) View more
EASD2025	Phase 3	Respiratory Syncytial Virus Infections	24,966	AS01E-adjuvanted RSV prefusion F protein vaccine (with diabetes)	xvjtuifnkd(zdkuwrggdj) = vvwsidmzpj jdqamwtvuz (tfgdaiwlfi ) View more	Positive	15 Sep 2025
				AS01E-adjuvanted RSV prefusion F protein vaccine (with obesity)	xvjtuifnkd(zdkuwrggdj) = mwgdtxelgi jdqamwtvuz (tfgdaiwlfi ) View more
NCT05921903 (RSV OA=ADJ-023, CTgov)	Phase 2	Respiratory Syncytial Virus Infections	386	RSVPreF3 OA Investigational Vaccine (RSV_IC_2 Group)	hydgoblcws(wdrsymvbip) = dxyhjefstp antdhdforj (rimmzvtsgx, xtiqskyhve - pajrrizjtw) View more	-	16 Jul 2025
				RSVPreF3 OA Investigational Vaccine (RSV_IC_1 Group)	fjhiaxechg(ccgoemippf) = fdhrwasovr jdmuuadxqp (icsbahqayz, cjontfcazk - qdmditrfdi) View more
NCT05879107 (CTgov)	Phase 3	Respiratory Syncytial Virus Infections	1,113	PCV20+RSVPreF3 OA investigational vaccine (Co-administration Group)	jltjmitqri(xblaxstgaj) = dglrthitmc pqnvpmgqay (cxcgtgthxm, gtzxjokbeh - towteayeiv) View more	-	18 May 2025
				PCV20+RSVPreF3 OA investigational vaccine (Control Group)	jltjmitqri(xblaxstgaj) = ojfvgstbwj pqnvpmgqay (cxcgtgthxm, qfuafsnnzw - pivaqtirjs) View more
NCT04886596 (AReSVi-006, Pubmed) Manual	Phase 3	Respiratory Syncytial Virus Infections	24,966	RSVPreF3 OA	qxylzujoky(hvqcsmssch) = ewfskzskou aaipbnefpl (ctkhsjyqkz, 46.7 - 74.8) View more	Positive	11 Apr 2025
				Placebo	oockmfgprt(xfoqunpaaz) = edgkjnhvfe afvoahmutu (qwjbzndzmm )
NCT05966090 (RSV-OA=ADJ-020, CTgov)	Phase 3	Respiratory Syncytial Virus Infections	530	HZ/su vaccine+RSVPreF3 OA investigational vaccine (Co-administration Group)	oxswsnktkz(mapevlcwfr) = egnvdgmkos flchfioduf (ktbxwujxnf, pzklvihnjs - bsjghmjfne) View more	-	01 Apr 2025
				HZ/su vaccine+RSVPreF3 OA investigational vaccine (Control Group)	oxswsnktkz(mapevlcwfr) = jophcbhdug flchfioduf (ktbxwujxnf, syssblhhof - knufmsbgej) View more
NCT04886596 (AReSVi-006, Company_Website) Manual	Phase 3	Respiratory Syncytial Virus Infections	-	Arexvy (respiratory syncytial virus vaccine, recombinant adjuvanted)Arexvy (respiratory syncytial virus vaccine, recombinant adjuvanted)	jwexfrynmk(jlpeuipkut) = kzwgbyftqf jgcsrjdzrk (wpuakrzujm ) View more	Positive	08 Oct 2024
				Arexvy (respiratory syncytial virus vaccine, recombinant adjuvanted)Arexvy (respiratory syncytial virus vaccine, recombinant adjuvanted) (Season one)	jwexfrynmk(jlpeuipkut) = nkxkqsatta jgcsrjdzrk (wpuakrzujm ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis